Nowadays, numerous forms and questionnaires including those for patients with chronic liver disease are developed and successfully tested for almost every common nosology. The most widely used questionnaire is the 36-Item Short Form Health Survey (SF-36). However, the disadvantage of the SF-36 includes insufficiently sensitive reduction in scales during deterioration in the patient’s condition. The Chronic Liver Disease Questionnaire (CLDQ) used in our study is better in this regard. The analysis of the results of interviewing showed significant differences among different groups. The average amount of received points was the largest in the control group, and the smallest in the experimental subgroup II (patients with cirrhosis). A significant difference was also noted in individual scales of the questionnaire. The signs of fatigue were almost identical in the control group and the experimental subgroup I, however, in the group with cirrhosis they were two times less. In this group people complaining of abdominal symptoms including bloating, abdominal pain and discomfort, and decrease in overall activity prevailed. The same group of patients reported the symptoms of anxiety, temper tantrum and sleep disturbances more often. People with chronic diffuse inflammation of the liver (the experimental subgroup I) differed significantly from healthy patients of the control group by characteristics reflecting anxiety levels, dietary habits, overall capacity, and abdominal symptoms to a somewhat lesser extent.
Younossi ZM, Boparai N, McCormick M, et al. Assessment of utilities and health-related quality of life in patients with chronic liver disease.Am J Gastroenterol. 2001;96:579-583.
Bader FZ. Correlation of quality of life in patients of cirrhosis of liver with etiology and disease severity using disease-specific quality questionnaire. Ayub Med Coll Abbottabad. 2007;19(2):7-12.
Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal. Gut. 2000;47:444-454.
Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295-300.
Gozhenko AI, Susla AB, Sidorenko OL, et al. The effect of arginine glutamate and meldonium combination on chronic inflammation and the endothelial function in patients cardiac valve calcification on the predialysis stage of chronic kidney disease. Bukovynskyi medychnyi visnyk. 2012;16(3):83-88.
Hauser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol. 2004;2:157-163.
Kanwal F, Hays RD, Kilbourne AM, et al Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol. 2004;99:1726-1732.
Novik АА, Ionova TI. Guide to the study of quality of life in medicine. OLMA Media Grupp. Moscow. 2007;320.
Serenko KА, Abdurakhmanov DT, Alekseeva VM. Analysis of studies of quality of life in patients with chronic hepatitis C. Zdravookhranenie segodnya. 2010;1:67-79.
Solomenchuk ТМ, Semehen-Bodak KhV. Modern myocardial cytoprotection in ischemic heart disease: a rational choice of drug.Mystetstvo likuvannia. 2011;4:56-61.
Stepanov YuМ, Zyhalo EV. Analysis of studies of quality of life in patients with chronic diffuse inflammatory liver diseases. Zhurfond. Dnipropetrovsk. 2012;46:502.
Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. JAMA. 1989;262:907-913.
The World Health Organization Quality of Life Assessment. Field Trial Version for Adults. Administration Manual. Geneva. WHO.1995; Available from: http://www.sciencedirect.com/science/article/pii/027795369500112K
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.